A Review of Treatments Targeting DNA-repair Gene Defects in Metastatic Castration Resistant Prostate Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Mar 31

PMID 36998466

Authors

Diana V Maslov

Quinne Sember

Jason Cham

Munveer Bhangoo

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is the most common cancer in men. About 6% of those diagnosed will develop metastatic disease. Unfortunately, metastatic prostate cancer is fatal. Prostate cancer can be castration sensitive or castration resistant. Many treatments have been shown to improve progression free survival and overall survival in metastatic castration resistant prostate cancer (mCRPC). In recent years, studies have been exploring targeting mutations in the DNA Damage Repair (DDR) response that may amplify oncogenes. In this paper, we aim to discuss DDR, new approved targeted therapies, and the most recent clinical trials in the setting of metastatic CRPC.

References

Ayoub N, Al-Shami K, Alqudah M, Mhaidat N . Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents. Onco Targets Ther. 2017; 10:4869-4883. PMC: 5634371. DOI: 10.2147/OTT.S148604. View

Rawla P . Epidemiology of Prostate Cancer. World J Oncol. 2019; 10(2):63-89. PMC: 6497009. DOI: 10.14740/wjon1191. View

Neeb A, Herranz N, Arce-Gallego S, Miranda S, Buroni L, Yuan W . Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. Eur Urol. 2020; 79(2):200-211. DOI: 10.1016/j.eururo.2020.10.029. View

Taylor B, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver B . Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1):11-22. PMC: 3198787. DOI: 10.1016/j.ccr.2010.05.026. View

Berthold D, Pond G, de Wit R, Eisenberger M, Tannock I . Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol. 2008; 19(10):1749-53. DOI: 10.1093/annonc/mdn288. View

Zhou Y, Bolton E, Jones J . Androgens and androgen receptor signaling in prostate tumorigenesis. J Mol Endocrinol. 2014; 54(1):R15-29. DOI: 10.1530/JME-14-0203. View

Mitra A, Fisher C, Foster C, Jameson C, Barbachanno Y, Bartlett J . Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer. 2008; 98(2):502-7. PMC: 2361443. DOI: 10.1038/sj.bjc.6604132. View

Zhou S, Dai Z, Wang L, Gao X, Yang L, Wang Z . MET inhibition enhances PARP inhibitor efficacy in castration-resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways. J Cell Mol Med. 2021; 25(24):11157-11169. PMC: 8650038. DOI: 10.1111/jcmm.17037. View

Tryggvadottir L, Vidarsdottir L, Thorgeirsson T, Jonasson J, Olafsdottir E, Olafsdottir G . Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst. 2007; 99(12):929-35. DOI: 10.1093/jnci/djm005. View

10.

Deshayes E, Roumiguie M, Thibault C, Beuzeboc P, Cachin F, Hennequin C . Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017; 11:2643-2651. PMC: 5593411. DOI: 10.2147/DDDT.S122417. View

11.

Antonarakis E, Velho P, Fu W, Wang H, Agarwal N, Sacristan Santos V . -Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO Precis Oncol. 2020; 4:370-381. PMC: 7252221. DOI: 10.1200/po.19.00399. View

12.

Wang J, Xu W, Wei Y, Zhu Y, Qin X, Zhang H . Elevated MRE11 expression associated with progression and poor outcome in prostate cancer. J Cancer. 2019; 10(18):4333-4340. PMC: 6691708. DOI: 10.7150/jca.31454. View

13.

Wright W, Shah S, Heyer W . Homologous recombination and the repair of DNA double-strand breaks. J Biol Chem. 2018; 293(27):10524-10535. PMC: 6036207. DOI: 10.1074/jbc.TM118.000372. View

14.

Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R . Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2019; 21(1):162-174. PMC: 6941219. DOI: 10.1016/S1470-2045(19)30684-9. View

15.

Turco F, Gillessen S, Cathomas R, Buttigliero C, Vogl U . Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs. Res Rep Urol. 2022; 14:339-350. PMC: 9529226. DOI: 10.2147/RRU.S360444. View

16.

Thompson D, Easton D . Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002; 94(18):1358-65. DOI: 10.1093/jnci/94.18.1358. View

17.

Messina C, Cattrini C, Soldato D, Vallome G, Caffo O, Castro E . BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications. J Oncol. 2020; 2020:4986365. PMC: 7492871. DOI: 10.1155/2020/4986365. View

18.

Wilkes D, Sailer V, Xue H, Cheng H, Collins C, Gleave M . A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents. Cold Spring Harb Mol Case Stud. 2017; 3(5). PMC: 5593159. DOI: 10.1101/mcs.a001487. View

19.

Michels J, Montemurro T, Murray N, Kollmannsberger C, Chi K . First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?. Cancer. 2006; 106(5):1041-6. DOI: 10.1002/cncr.21695. View

20.

Abbas A, Gupta S . The role of histone deacetylases in prostate cancer. Epigenetics. 2008; 3(6):300-9. PMC: 2683066. DOI: 10.4161/epi.3.6.7273. View